Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Male or female recipients 18-65 years of age undergoing primary or secondary kidney transplantation~Recipients of primary or secondary cadaveric, ECD/DCD kidney (defined as follows)~Donor whose heart has irreversibly stopped beating, previously referred to as non-heart-beating or asystolic donation~Brain-dead donor \> 60 years old~Donor aged 50-59 years old with two of the following criteria:~History of hypertension~Terminal serum creatinine ≥ 1.5 mg/dL~Death resulting from cerebrovascular accident~Patients who have given written informed consent to participate in the study~Exclusion Criteria:~Cold ischemic time (CIT) \> 30 hours~Patients who are ABO incompatible transplants, or T, or B cell crossmatch positive transplant~Patients with a known hypersensitivity to any of the study drugs or to drugs of similar chemical class~Non-controlled DCD~Donor age \>70~Patients with BMI \>32 at baseline before surgery~Pregnant or lactating females~Females of childbearing potential unwilling to use an effective means of contraception or are planning to become pregnant~Patients with platelet count \<100,000/mm3 at the evaluation before randomization.~Patients with an absolute neutrophil count of \< 1,500/mm³ at baseline before surgery or white blood cell count of \< 4,500/mm³~Patients who are recipients of multiple solid organ transplants~Patients who have severe hypercholesterolemia (\>350 mg/dL; \>9 mmol/L) or hypertriglyceridemia (\>500 mg/dL; \>5.6 mmol/L). Patients with controlled hyperlipidemia are acceptable~Patients who have an abnormal liver profile such as ALT, AST, Alk Phos or total bilirubin \>3 times the upper normal limit~Patients who are treated with drugs that are strong inducers or inhibitors of cytochrome P450 3A4, such as terfenadine, astemizole, cisapride, erythromycin, azithromycin, itraconazole, rifampin or lovastatin~Patients who received an investigational drug or who have been treated with a non-protocol immunosuppressive drug or treatment within 30 days or 5 half-lives prior to randomization~Patients with a history of malignancy of any organ system, treated or untreated, within the past 2 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin~Patients who are HIV-positive or Hepatitis C (PCR+ only) or B surface antigen positive~Recipients of organs from donors who test positive for Hepatitis B surface antigen or Hepatitis C (PCR+ only) are excluded~Patients with a history of severe diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus (Hgb A1c \<7.0 %) at baseline~Patients who have any surgical or medical condition, which in the opinion of the investigator, might significantly alter the absorption, distribution, metabolism and excretion of study medication, and/or the presence of severe diarrhea or active peptic ulcer~Patients who have cardiac failure (e.g. resting dyspnea, symptoms with less than ordinary activity, marked limitation of activity) at time of screening or any other severe cardiac disease as determined by the investigator~Patients with abnormal physical or laboratory findings of clinical significance within 3 months of randomization which would interfere with the objectives of the study~Patients with any history of coagulopathy or medical condition requiring long-term anticoagulation therapy after transplantation (Low dose aspirin treatment is allowed)~Patients with known history of focal segmental glomeruloscrelosis~Presence of psychiatric illness (i.e., schizophrenia, bipolar, major depression) that, in the opinion of the investigator, would interfere with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ERL & TAC (Type: EXPERIMENTAL): Concentration controlled everolimus(ERL) \& Low dose tacrolimus(TAC) + corticosteroid withdraw
- ERL & TAC --> MMF/MPA (Type: EXPERIMENTAL): Concentration controlled everolimus \& low dose tacrolimus --\> mycophenolate mofetil (MMF) at Month 3 + corticosteroid
- Standard dose TAC + MMF/MPA (Type: EXPERIMENTAL): Standard dose of tacrolimus + mycophenolate mofetil + corticosteroid withdraw

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues